Publication | Closed Access

Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite

Significant Cardioprotective EffectsBiochemistryIron Chelating MetaboliteMedicineClinical PharmacologyPharmacotherapyTopoisomerase IibetaMetabolomicsCardiovascular ToxicityPharmacologyDrug DiscoveryOxidative Stress